Overview
- King's College London published peer-reviewed findings in Clinical Toxicology indicating that post-mortem testing often fails to detect nitazenes.
- Laboratory work using anaesthetised animal models found that, under real-world handling, only about 14% of the drug present at overdose remained detectable.
- Modelling of UK National Programme on Substance Use Mortality data pointed to a roughly 33% excess of drug deaths in Birmingham in 2023 that could be consistent with non-detection.
- Typical waits of around a month before toxicology analysis may allow substantial nitazene breakdown, contributing to missed identifications in coronial cases.
- Context from officials shows scale and response, with the NCA reporting 333 nitazene-linked fatalities in 2024 and the government funding treatment, wider naloxone use, and Border Force detection efforts.